Array BioPharma Revenue and Competitors
Estimated Revenue & Valuation
- Array BioPharma's estimated annual revenue is currently $195M per year.
- Array BioPharma received $6.2M in venture funding in December 2017.
- Array BioPharma's estimated revenue per employee is $1,598,361
- Array BioPharma's total funding is $121.4M.
- Array BioPharma's current valuation is $10.3M. (July 2019)
Employee Data
- Array BioPharma has 122 Employees.
- Array BioPharma grew their employee count by 0% last year.
Array BioPharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | COO | Reveal Email/Phone |
2 | COO | Reveal Email/Phone |
3 | CFO | Reveal Email/Phone |
4 | CEO | Reveal Email/Phone |
5 | VP, Global Market Analytics | Reveal Email/Phone |
6 | SVP HR | Reveal Email/Phone |
7 | Associate Director, Drug Product Manufacturing | Reveal Email/Phone |
8 | Chief Scientific Officer | Reveal Email/Phone |
9 | Sr. Director, Clinical Research Scientist | Reveal Email/Phone |
10 | Associate Director Clinical Pharmacology | Reveal Email/Phone |
Array BioPharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 25 | 0% | N/A | N/A |
#2 | $10.3M | 51 | 6% | N/A | N/A |
#3 | $4.4M | 22 | -8% | N/A | N/A |
#4 | $195M | 122 | 0% | $121.4M | N/A |
#5 | $4.8M | 24 | -20% | N/A | N/A |
#6 | $6.8M | 34 | -19% | N/A | N/A |
#7 | $4.8M | 24 | 0% | N/A | N/A |
#8 | $4M | 40 | -11% | $138M | N/A |
#9 | $4.8M | 24 | -14% | N/A | N/A |
#10 | $69.5M | 346 | -6% | N/A | N/A |
What Is Array BioPharma?
Array BioPharma Inc. (NASDAQ: ARRY) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Eight registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics). We have locations in Boulder, CO; Cambridge, MA; and Morrisville, NC.
keywords:Biotechnology,Cleantech,Healthcare,Medical Devices,Medical Diagnostics,Pharmaceuticals,Wind Power
$121.4M
Total Funding
122
Number of Employees
$195M
Revenue (est)
0%
Employee Growth %
$10.3M
Valuation
N/A
Accelerator
Array BioPharma News
Array BioPharma Inc, Pfizer Inc, Portola Pharmaceuticals Inc, Bristol-Myers Squibb Company, Nimbus Therapeutics LLC, Sareum Holdings Plc,...
Array BioPharma Inc, Pfizer Inc, Portola Pharmaceuticals Inc, Bristol-Myers Squibb Company, Nimbus Therapeutics LLC, Sareum Holdings Plc,...
Consulting or Advisory Role: Agenus, Akeso Biopharma, Amgen, Aravive, AstraZeneca ... Janssen (Inst), Array BioPharma (Inst), Tesaro (Inst),...
Other Companies in Boulder
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $30M | 122 | 47% | N/A |
#2 | $3.9M | 123 | 54% | $271.7M |
#3 | $22.5M | 125 | -7% | N/A |
#4 | $15M | 125 | 8% | N/A |
#5 | $25.6M | 125 | -6% | N/A |
Array BioPharma Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2002-02-14 | $30.0M | Public Offering | Article | |
| 2008-05-06 | $80.0M | Undisclosed | Deerfield Management | Article |
| 2008-12-24 | $40.0M | Undisclosed | Deerfield Management | Article |
| 2009-05-20 | $40.0M | Undisclosed | Deerfield Management | Article |
| 2009-09-21 | $25.0M | Undisclosed | Piper Jaffray | Article |
| 2012-11-12 | $65.7M | Undisclosed | Jefferies & Company Inc, JP Morgan Securities LLC | Article |
| 2013-06-05 | $100.0M | Undisclosed | Goldman Sachs & Co, J.P Morgan Securities LLC | Article |
| 2013-06-10 | $17.2M | Undisclosed | Goldman Sachs & Co, JP Morgan Securities LLC | Article |
| 2016-09-20 | $1.4M | Undisclosed | Redmile Group | Article |
| 2016-10-04 | $132.2M | Undisclosed | Multiple | Article |
| 2017-09-15 | $258.7M | Undisclosed | J.P. Morgan Securities LLC | Article |
| 2017-12-05 | $6.2M | Undisclosed | Article |